TITLE

Aldosterone Antagonists � Last Man Standing?

AUTHOR(S)
Armstrong, Paul W.
PUB. DATE
January 2011
SOURCE
New England Journal of Medicine;1/6/2011, Vol. 364 Issue 1, p79
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The author reflects on aldosterone antagonists in the treatment of heart failure. It says that in the turn of the millennium, there are four cardiac medicines developed before 1960 that survived namely aspirin, digoxin, warfarin and spironolactone. It highlights two studies whose findings have made aldosterone-receptor blockade to become part of recommended therapy in patients with functional class III or IV heart failure and those recovering from acute myocardial infarction with complicating left ventricular dysfunction.
ACCESSION #
57220979

 

Related Articles

  • The Risks and Benefits of Therapy with Aldosterone Receptor Antagonist Therapy. Sica, Domenic A. // Current Drug Safety;Jan2007, Vol. 2 Issue 1, p71 

    Spironolacotone and eplerenone are mineralocorticoid-blocking agents. These compounds block both the epithelial and non-epithelial actions of aldosterone with the latter assuming increasing clinical importance. Spironolactone and eplerenone both effectively reduce blood pressure either as mono-...

  • Hyperkalaemia in the age of aldosterone antagonism. Chapagain, A.; Ashman, N. // QJM: An International Journal of Medicine;Nov2012, Vol. 105 Issue 11, p1049 

    Hyperkalaemia is well recognized as a medical emergency. However, with the publication of trials showing benefit with renin-aldosterone axis suppression in heart failure, the epidemiology of patients presenting with hyperkalaemia has changed. The reported incidence of rate of serious...

  • Aldactide 50.  // Royal Society of Medicine: Medicines;2002, p42 

    The article presents information on Aldactide 50, a proprietary, prescription-only compound preparation of the aldosterone-antagonist and potassium-sparing spironolactone and the thiazide-type diuretic hydroflumethiazide. This drug can be used for heart failure treatment and is available as tablets.

  • Spironolactone.  // Reactions Weekly;3/10/2007, Issue 1142, p21 

    The article presents a case report of a man with congestive heart failure and was receiving spironolactone daily. It states that a condition called gynecomastia which is an increasing breast size in the patient during his treatment made his medication replaced by eplerenone. The author mentions...

  • Aldosterone Antagonists: The Most Underutilized Class of Heart Failure Medications. Guglin, Maya; Awad, Khaled Esmaeel; Polavaram, Latha; Vankayala, Hema // American Journal of Cardiovascular Drugs;2007, Vol. 7 Issue 1, p75 

    BACKGROUND: Aldosterone antagonists have been proven to be beneficial in severe heart failure (HF) as a result of systolic dysfunction. We sought to determine if there is a disparity in their utilization compared with ACE inhibitors and β-adrenoceptor antagonists (β-blockers). METHODS:...

  • Eplerenone Use for Mild Symptomatic Heart Failure? Crawford, Michael H. // Clinical Cardiology Alert;Mar2011, Vol. 30 Issue 3, p17 

    In this article the author questions the use of eplerenone as an alternative to spironolactone in systolic heart failure (HF) patients with mild symptoms, by referencing a study by F. Zannad and colleagues. He presents details related to the study, and opines that its unique features have...

  • Early Spironolactone Treatment Attenuates Heart Failure Development by Improving Myocardial Function and Reducing Fibrosis in Spontaneously Hypertensive Rats. Cezar, Marcelo D.M.; Damatto, Ricardo L.; Pagan, Luana U.; Lima, aline R.R.; Martinez, Paula F.; Bonomo, Camila; Rosa, Camila M.; Campos, Dijon H.S.; Cicogna, antonio C.; Gomes, Mariana J.; Oliveira-Jr, Silvio a.; Blotta, Daniella a.; Okoshi, Marina P.; Okoshi, Katashi // Cellular Physiology & Biochemistry (Karger AG);Jul2015, Vol. 36 Issue 4, p1453 

    Background: We evaluated the role of the aldosterone blocker spironolactone in attenuating long-term pressure overload-induced cardiac remodeling and heart failure (HF) in spontaneously hypertensive rats (SHR). Methods and Results: Thirteen month-old male SHR were assigned to control (SHR-C,...

  • Aldosterone Receptor Antagonists for Hypertension: What Do They Offer? Liew, Danny; Krum, Henry // Drugs;2003, Vol. 63 Issue 19, p1963 

    Aldosterone is an important and independent target for therapeutic intervention in hypertension and hypertension-related diseases. Its actions, once thought to be limited to the distal convoluted tubule of the kidney, are now recognised to be wide-ranging, including interactions with...

  • Warfarin doesn't prevent death.  // Neurology Alert;Jul2012 Pharmacology Watch, p1 

    The article discusses a study that indicated that warfarin is no more effective than aspirin in preventing mortality in patients with heart failure who are not in atrial fibrillation (AF).

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics